NasdaqGM:VCYTBiotechs
Veracyte’s ASCO Urology Data And TrueMRD Launch Test Investor Patience
Veracyte, ticker NasdaqGM:VCYT, plans to present more than 15 abstracts from its urology portfolio at the 2026 ASCO Genitourinary Cancers Symposium.
The company is preparing to launch its TrueMRD test for muscle invasive bladder cancer and continues to build out its broader genomic testing offerings.
Veracyte enters this news cycle with its shares at $35.72 and a mixed return profile, including a 50.7% gain over three years alongside a 15.7% decline year to date and a 12.0% decline over the...